
compani
usd feb pm et
summari larg produc brand prescript drug offer wide rang treatment
neurolog disord diabet cancer condit
nm price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra keep hold
compani lift
target
ep estim -- roughli line
histor forward price-to-earnings averag ep
vs line consensu lower
ep estim
start sale yoy
driven growth volum partial
off-set decreas price
neg currenc impact growth led
diabet drug trulic yoy
basaglar yoy well
psoriasi drug taltz yoy
robust demand growth three drug
account total sale
year ago total revenu growth hinder
loss exclus ciali
revenu howev face new gener
competit saw annual sale
declin expect gener
revenu growth around
rapid growth success newer drug
balanc declin older one without
risk assess reflect relentless effort
gener challeng compani brand drug
intens competit brand drug
current indic uncertainti around drug
develop regulatori approv process
risk partial mitig divers product
portfolio drug gener
sale robust drug develop pipelin
compani typic drug phase
later stage regulatori approv success
approv pipelin drug like sustain
apr ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
vice-president financ
compani
corpor overview co lead maker prescript drug offer wide rang
treatment neurolog disord diabet cancer condit compani anim health
busi oper elanco divis develop manufactur market product
food anim companion anim compani product sold approxim countri
compani endocrinolog product includ humalog insulin analog treatment diabet
humulin human insulin recombin dna origin treatment diabet trajenta
treatment type diabet jentadueto combin tablet linagliptin trajenta metformin
hydrochlorid use treatment type diabet jardianc treatment type diabet
approv europ japan trulic treatment type diabet approv
 europ glyxambi combin tablet linagliptin empagliflozin jardianc
treatment type diabet approv januari forteo treatment
osteoporosi postmenopaus women men high risk fractur glucocorticoid-induc
osteoporosi men postmenopaus women evista prevent treatment
osteoporosi postmenopaus women reduct risk invas breast cancer
postmenopaus women osteoporosi postmenopaus women high risk invas breast
cancer humatrop treatment human growth hormon defici certain pediatr growth
condit axiron topic solut testosteron appli underarm applic replac
therapi men certain condit associ defici absenc testosteron
compani neurosci product includ cymbalta treatment major depress disord
diabet peripher neuropath pain gener anxieti disord manag
fibromyalgia chronic musculoskelet pain due chronic low back pain chronic pain due
osteoarthr zyprexa treatment schizophrenia acut mix manic episod associ
bipolar disord bipolar mainten strattera treatment attention-deficit hyperact
disord prozac treatment major depress disord obsessive-compuls disord bulimia
nervosa panic disord amyvid radioact diagnost agent positron emiss tomographi
imag beta-amyloid neurit plaqu brain adult patient cognit impair
evalu alzheim diseas caus cognit declin
compani anim health segment elanco includ food product anim rumensin
cattl feed addit improv feed effici growth also control prevent coccidiosi
posilac protein supplement improv milk product dairi cow paylean optaflexx lean
perform enhanc swine cattl respect tylan antibiot use control certain
diseas cattl swine poultri micotil pulmotil pulmotil ac antibiot use treat respiratori
diseas cattl swine poultri respect coban monteban maxiban anticoccidi agent
use poultri surmax sold maxu countri perform improv swine
compani product companion anim includ trifexi monthli chewabl tablet dog
kill flea prevent flea infest prevent heartworm diseas control intestin parasit
infect comforti chewabl tablet kill flea prevent flea infest dog
impact major develop januari compani complet acquisit novarti
anim health product acquir novarti deal includ denagard antibiot control
treatment respiratori enter diseas swine poultri milbemax spectrum intestin
wormer given monthli also offer prevent heartworm sentinel outsid
monthli tablet prevent flea popul concurr prevent heartworm diseas
treatment roundworm hookworm whipworm dog atopica treatment chronic
manifest atop dermat dog symptomat treatment chronic allerg
dermat cat fortekor treatment congest heart failur dog reduct
proteinurea associ chronic kidney diseas cat
pipelin spend total billion billion billion billion
equal sale respect one highest
 d-to-sal ratio drug industri industri averag approxim sale april
compani pipelin new chemic entiti new molecular entiti
nme phase clinic trial phase ii clinic trial
financi trend sale risen billion billion repres
three-year compound annual growth rate compound-annual-growth-rate growth new product sale partial
off-set impact patent expir sever product gross margin improv
adjust ep rose repres three-year
compound-annual-growth-rate
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc decemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
outlook pharmaceut sub-industri
next year posit reflect
strong novel drug approv nda activ
food drug administr fda --
posit brand drug maker
repres lion share
improv gener profit margin
competit appear moder
overal posit view somewhat temper
expect lower growth overal
expect strong pace nda continu
next year aid continu robust
growth invest led major brand drug
compani banner year nda
fda new drug approv
repres surg approv compar
mani
new drug littl competit
provid tailwind brand drug
maker strong growth spend
primari driver novel approv uptick
industri increas
estim pace anoth year
growth septemb
growth mark rapid acceler
averag annual growth
side sub-industri
outlook earn growth gener
maker posit closer neutral fda
gener approv total
mani
compet version gener enter
sever gener
price deflat becam norm profit margin
contract surprisingli number
firm announc asset divestitur exit
 gener industri
bright side think lower competit
start impact note gener
approv tick vs
first materi declin least six
year also note move
averag gener applic lead
think anoth sign
mitig competit allow
moder gener deflat
modest improv gener profit margin
year ahead
anoth boost gener maker
record year fda first-gener approv
experienc
first-gener typic enter
market materi lower price
brand-nam counterpart allow
quick market share gain accordingli
major increas first-gener provid
revenu tailwind gener maker next
mitig posit outlook
sub-industri expect slower
prescript volum growth next
year strong gain health-insur
popul driven solid employ
growth view
think gain harder come
 approach full employ
remov tailwind prescript
volum growth assum
slower growth health plan roll gener
mean slower growth prescript volum
versu rise composit
drop
year date januari pharma
slip gain
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
keep target ep
estim tax reform benefit ep vs
ahead estim sale rose pharmaceut sale
driven strong sale new drug trulic taltz jardianc top sell
drug humalog ciali fell respect humalog sale
impact lower price due discount rebat also concern
declin anim health lower volum market access
headwind competit pressur posilac optiplex /jeffrey loo cfa
et cfra keep hold opinion share eli lilli
compani rais target peer
forward ep estim faster growth ep
vs in-lin estim rais ep
estim sale rose driven new
drug trulic taltz world-wide diabet sale rose
explor potenti spin-off sale expect
provid updat elanco sale
second largest anim health compani view potenti move posit
analyst research note compani news
et cfra keep hold opinion share compani
lift target
ep estim -- roughli line histor forward price-to-earnings averag
ep vs line consensu lower ep
estim start sale yoy
driven growth volum partial off-set decreas price
neg currenc impact growth led diabet drug trulic
yoy basaglar yoy well psoriasi drug
taltz yoy robust demand growth three drug
account total sale year ago total revenu growth
hinder loss exclus ciali revenu howev
face new gener competit saw annual sale declin
expect gener revenu growth around rapid
growth success newer drug balanc declin older one without
compani rais target
ep estim line histor averag forward price-to-earnings ep
vs consensu rais ep estim
sale yoy higher
volum partial off-set lower averag price growth led
diabet drug trulic yoy psoriasi drug taltz
yoy robust demand also improv margin
quarter cog sg grow slower revenu
combin effect strong sale growth cost contain estim
yoy increas adj pre-tax incom pipelin encourag fda
approv emgal migrain treatment think
competit sever new migrain drug approv year june
acquisit phase pegilodecakin think promis orphan
drug pancreat cancer /colin scarola
et cfra keep hold opinion share eli li
rais target in-lin peer
forward ep estim adjust ep vs
ahead estim aid lower-than-expect oper
cost due cost reduct effort improv product rais
ep estim ep estim
sale rose pharmaceut sale driven new product
trulic taltz cyramza basaglar also encourag
pipelin advanc phase trial tanezumab treat
osteoarthr met three co-primari endpoint empagliflozin treat
diabet also met primari endpoint announc spin
elanco anim health unit ipo say maxim
after-tax valu sharehold view spin-off posit
anim health unit struggl past year soft sale /jeffrey
et cfra keep hold opinion share eli lilli
compani keep target price line
peer ep estim rais
ep estim ep vs
ahead estim sale aid fx benefit rose driven
increas demand new drug trulic talz
basaglar oper cost fell drive oper
margin bp diabet volum growth rose note continu
soft anim health expect growth unit
separ fda advisori panel recommend approv baricitinib treat
moderate-to-sever rheumatoid arthriti dosag
approv dosag safeti concern particularli pulmonari
embol deep vein thrombosi note dose approv
europ expect work fda dose believ
dose key gain market share /jeffrey loo cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
compani
